Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives

Journal of Hypertension, Supplement

Volumn 19, Issue 1, 2001, Pages

  Ball, K J ^a   Williams, P A ^a   Stumpe, K O ^a  

^a Old School Surgery   (United Kingdom)

Author keywords

Angiotensin II receptor antagonist; Atenolol; Captopril; Comparator; Efficacy; Essential hypertension; Hydrochlorothiazide; Losartan; Olmesartan medoxomil; Safety

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; OLMESARTAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HUMAN; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034951613     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200106001-00007     Document Type: Review

References (9)

1. Angiotensin II antagonism and the heart: Valsartan in left ventricular hypertrophy
2. Non-peptide angiotensin type I receptor antagonists in the treatment of hypertension
3. Angiotensin II antagonists lead the way in hypertension management
4. How do angiotensin II receptor antagonists affect blood pressure?
5. Comparative safety and tolerability of angiotensin II receptor antagonists
6. Angiotensin II-receptor antagonists: An overview
7. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinical relevant drug drug interactions
8. Safety and efficacy of angiotensin II receptor antagonists
9. Blood pressure and mortality among men with prior myocardial infarction: Multiple Risk Factor Intervention Trial Research Group